Skip to search formSkip to main contentSkip to account menu

MK 0859

Known as: MK-0859, MK0859 
National Institutes of Health

Related topics

Related topics

1 relation
anacetrapib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Pharmacokinetic drug evaluation of anacetrapib for the treatment of dyslipidemia
ABSTRACT Introduction: While some cholesteryl ester transfer protein inhibitors have had their clinical study interrupted because… 
2013
2013
Synthesis of stable isotope labeled anacetrapib, its major metabolites and [(14) C]anacetrapib.
Cholesteryl ester transfer protein inhibitors are an important class of compounds designed to treat hypocholesterolemia and… 
2011
2011
Effect of Diltiazem, a Moderate CYP3A Inhibitor, on the Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein Inhibitor, in Healthy Subjects
A (MK-0859) is a potent and selective inhibitor of cholesteryl ester transfer protein (CETP) currently undergoing development as… 
Review
2009
Review
2009
The end of the road for CETP inhibitors after torcetrapib?
Purpose of review Because high-density lipoprotein cholesterol (HDL-C) levels are inversely related to cardiovascular disease… 
2009
2009
Abstract 1272: Efficacy and Safety Following Cessation of Treatment With Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib (MK-0859) in Patients With Primary Hypercholesterolemia or Mixed…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)